Last quarter (Q2 2023), GT Biopharma's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, GT Biopharma's net income was $-1.99M. See GT Biopharma’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	-	-	$ 0.00	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ -29.76M	$ 21.26M	$ 57.52M	$ 6.76M	$ 11.46M	$ 21.55M
Operating Income	$ -12.76M	$ -21.26M	$ -57.52M	$ -6.76M	$ -11.46M	$ -21.55M
Net Non Operating Interest Income Expense	$ 597.00K	$ 284.00K	$ -680.00K	$ -3.32M	$ -2.13M	$ -9.12M
Other Income Expense	$ 2.12M	$ -89.00K	$ -182.00K	$ -18.21M	$ -25.06M	$ -228.51M
Pretax Income	$ -14.21M	$ -20.88M	$ -58.01M	$ -28.30M	$ -38.65M	$ -259.19M
Tax Provision	-	-	-	-	$ 0.00	$ 0.00
Earnings From Equity Interest Net Of Tax	-	$ 119.00K	-	-	-	-
Net Income Common Stockholders	$ -14.21M	$ -20.88M	$ -58.01M	$ -28.30M	$ -38.65M	$ -259.19M
Basic EPS	-	-	-	-	-	-
Diluted EPS	-	-	-	-	-	-
Basic Average Shares	-	-	-	-	-	-
Diluted Average Shares	-	-	-	-	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ -29.76M	$ 21.26M	$ 57.52M	$ 6.76M	$ 11.46M	$ 21.55M
Net Income From Continuing And Discontinued Operation	$ -14.68M	$ -20.90M	$ -58.01M	$ -28.30M	$ -38.65M	$ -259.19M
Normalized Income	$ -8.49M	-	-	$ -22.68M	$ -13.59M	$ -30.67M
Interest Expense	-	-	-	$ 3.32M	$ 2.13M	$ 9.12M
EBIT	$ -14.70M	$ -20.88M	$ -57.33M	$ -24.98M	$ -36.52M	$ -250.07M
EBITDA	$ -12.65M	$ -20.78M	$ -57.33M	$ -24.98M	$ -36.52M	$ -250.06M

Currency in USD

GT Biopharma Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing